Clinical Trial Update: GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating GM-CSF and thalidomide in patients undergoing surgery for high-risk prostate cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• GM-CSF (granulocyte-macrophage colony-stimulating factor)
• Thalidomide (thalidomide)

Snippet

Sponsor: The Cleveland Clinic | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-08-28